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Blackfoot disease is a peripheral vascular disease resulting in
gangrene of the lower extremities (Pan et al, 1993). The endemic
area is along the south-west coast in Taiwan (Tseng et al, 1968;
Brown et al, 1995; Tseng et al, 1995). People living in the endemic
area have a higher rate of skin, bladder, renal and lung cancers
than those in other areas (Chiang et al, 1993; Shibata et al, 1994).
Numerous studies have indicated that high levels of arsenic and
fluorescent substances are present in artesian well water of the
endemic area (Chen et al, 1988; Wu et al, 1989; Chiou et al, 1995;
Hsueh et al, 1995). Arsenic contamination of drinking water is
known to cause chronic poisoning and an association between the
effects of chronic exposure to a high level of arsenic in drinking
water and the occurrence of a variety of skin disorders, skin cancer
and blacfoot disease was found in 1968 (Tseng et al, 1968).
Recently, carcinogenesis has been studied using molecular bio-
logical methods. Carcinogenesis has been suggested as a multistep
process that occurs in a whole animal and needs multiple gene
alterations (Bishop et al, 1991). Some genes, for example p53,
have been found to be involved in carcinogenesis. In ultraviolet
(UV)-induced skin cancer Oram et al (1994) found that p53
tumour suppressor gene mutation rate was 50%; a similar mutation
rate was found by other authors (Brash et al, 1991; Sato et al,
1993; Ziegler et al, 1993; Matsumura et al, 1996). Most of the
mutation types are CC®TT transitions (Lubbe et al, 1994;
Nakazawa et al, 1994; Ziegler et al, 1994; Drouin et al, 1997). The
carcinogenesis of arsenic-related skin cancer, however, is very
different from that of UV-induced skin cancer. To understand the
role of p53 tumour suppressor gene in arsenic-related skin cancer,
we analysed p53 gene mutation in 39 cases with non-melanoma
skin cancer from the blackfoot disease endemic area. Furthermore,
we compared the carcinogenic mechanism of arsenic-related
cancers with that of UV-induced skin cancer.
MATERIALS AND METHODS
Specimen collections
All of the tumour tissue specimens of arsenic-related skin cancer
and normal tissue specimens were collected from patients living
in the blackfoot disease endemic area of Taiwan. The patients
included 23 patients with Bowen’s disease, seven patients with
basal cell carcinomas (BCC) and nine patients with squamous cell
carcinomas (SCC); 15 of the patients also had blackfoot disease.
All of the tumour specimens were collected from areas not gener-
ally exposed to the sun, including the inner thigh, upper back, loin,
interior upper arm and penis. In addition, the pathological biopsy
of the cancers did not reveal solar elastosis, which is caused by
sun damage (Weyers et al, 1996). The specimens were partially
formalin-fixed and wax-embedded. The other unfixed tissues were
fresh frozen in liquid nitrogen for DNA extraction.
DNA extraction
Genomic DNA was extracted from tissues by proteinase K diges-
tion and phenol–chloroform extraction according to Sambrook’s
method (Sambrook et al, 1989).
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PCR-SSCP analysis
To search for subtle mutation of the p53 gene using polymerase
chain reaction–single-strand conformation polymorphism (PCR-
SSCP) analysis, 11 different sets of primers for p53 coding regions
were used and are described below:
Exon 2: SR23LT: 5¢-AGCCAGACTGCCTTCCGGGTCA-3¢;
SR23RT: 5¢-TGGCATTCTGGGAGCTTC-3¢; Exon 4: SR4-1LT:
5¢-TGCCGTCCCAAGCAATGGAT-3¢; SR4-1RT: 5¢-
CTGGGAAGGGACAGAAGATGA-3¢; SR4-2LT: 5¢-GTGGC-
CCCTGCACCAGCAGCT-3¢; SR4-2RT:
5¢-CTCAGGGCTTCTGACCGTGCA-3¢; Exon 5: SR5-1LT: 5¢-
CTTTGCTGCCGTCTTCCAGTTCG-3¢; SR5-1RT: 5¢-CTAT-
CTGAGCAGCGCTCATG-3¢; SR5-2LT:
5¢-GCCATCTACAAGCAGTCA-3¢; SR5-2RT: 5¢-AGACC-
TAAGAGCAATGAGTG-3¢; Exon 6: SR6LT: 5¢-AGGTCTG-
GCCCCTCCTCAGC-3¢; SR6RT:
5¢-ACCTCAGGCGGCTCATAGGGCA-3¢;
Exon 7: SR7LT: 5¢-TCTCCTAGGTTGGCTCTGAC-3¢;
SR7RT: 5¢-CACAGCAGGCCAGTGTGCAG-3¢
Exon 8: SR8LT: 5¢-TGGGACAGGTAGGACCTGA-3¢; SR8RT:
5¢-TGAATCTGAGGCATAACTGCACC-3¢; Exon 9: SR9LT: 5¢-
GGAGCACCGCAGGGTGCAG-3¢; SR9RT: 5¢-CCCAA-
GACTTAGTACCTGAA-3¢; Exon 10: SR10LT:
5¢-CTCTGTTGCTGCAGATC-3¢; SR10RT: 5¢-GCTGAGGT-
CACTCACCT-3¢; Exon 11: SR11LT: 5¢-GAATTCTGTCTCC-
TACAGCCAC-3¢; SR11RT:
5¢-GAATTCTGACGCACAGGTATTGC-3¢.
The reaction mixture contained 50 pmol of each primer,
2.5 U Taq DNA polymerase (Promega Corp., Madison, WI,
USA), 100 mmol/l–1 of each deoxy-NTP, [a-32P]deoxy-CTP
(3000 Ci mmol–1; 10 Ci ml–1; New England Nuclear Research
Products, Boston, MA, USA), 1.5 mmol l–1 magnesium chloride,
50 mmol l–1 potassium chloride, 10 mmol l–1 Tris–HCl pH 8.3 and
gelatin at 10 mg ml–1. A programmable thermal cycler (PTC-100,
MJ Research, Watertown, MA, USA) was used to perform
40 cycles of for exons 2, 3, 4, 5, 6, 7, 10 and 11, at 58°C for
exon 8, and at 62°C for exon 9 with an extension for an additional
2 min at 72°C. Re-PCR of mutated DNA was done to ensure the
reproducibility.
Table 1 Results of p53 mutations in 39 cases with arsenic-related skin cancer
Case no. Sex Age Diagnosis Site No. of lesion SSCP Exon Codon a.a. base IMH BFD
1 M 57 BD Upper back 3 N – –
2 M 61 BD Loin (Lumbar) 3 N – –
3 M 64 BD Interior upper arm 5 M 7 249, AGG®AAG Arg®Lys + +
4 M 58 BD Loin (Lumbar) 2 M 8 292, AAA®AAT Lys®Asn + –
5 M 63 BD Penis 1 N – –
6 M 67 BD Interior thigh 3 M 5 149, TCC®TTC Ser®Phe + +
7 M 69 BD Abdomen 4 N – –
8 M 54 BD Abdomen 3 N + –
9 F 68 BD Interior upper arm 3 N – –
10 F 53 BD Neck 1 M 8 273, CGT®CCT Arg®Pro + +
11 F 73 BD Lower back 3 M 5 175, CGC®CAC Arg®His + +
12 F 64 BD Forehead 1 N + –
13 F 69 BD Upper back 4 N – –
14 F 65 BD Palm 1 N – –
15 M 72 BD Interior thigh 3 M 8 298, GAG®GAA Silent – –
16 M 53 BD Abdomen 4 M 5 175, CGC®CAC Arg®His + +
17 F 60 BD Lower back 2 N – –
18 F 65 BD Lower back 4 N + –
19 M 68 BD Interior upper arm 3 N – –
20 M 69 BD Abdomen 3 M 7 253, ACC®ACG Silent – –
21 F 67 BD Lower back 2 N – –
22 M 53 BD Interior thigh 1 M 5 175, CGC®CAC Arg®His + +
23 F 64 BD Loin 2 N – –
24 F 73 BCC Interior thigh 1 M 5 174, AGG®CGG Silent – +
25 M 67 BCC Abdomen 1 N – –
26 F 58 BCC Front of elbow 2 N – +
27 F 62 BCC Interior upper arm 1 N – –
28 M 71 BCC Upper back 2 N – –
29 M 73 BCC Loin (Lumber) 3 N – +
30 M 71 BCC Lower back 2 M 8 283, CGC®CTC Arg®Leu + +
31 F 60 SCC Lower back 1 M 5 172, GTT®GCT Val®Ala – +
32 M 56 SCC Interior thigh 1 N + +
33 F 67 SCC Penis 1 N – –
34 M 61 SCC Lower back 2 M 8 273, CGT®CCT Arg®Pro + +
35 F 73 SCC Abdomen 1 N – –
36 M 59 SCC Abdomen 2 M 8 284, ACA®AAA Thr®Lys + +
37 M 64 SCC Upper back 2 M 8 273, CGT®CCT Arg®Pro + +
38 F 68 SCC Penis 1 N – –
39 M 58 SCC Chest 2 M 8 289, CTC®CTG Silent – –
IMH: immunohistochemical staining; BFD: blackfoot disease.1082 C-H Hsu et al
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Direct sequencing
DNA extracts for DNA sequencing were amplified using the
primers SR4-2LT and SR5-1RT for the p53 exon 5 region, and
using the primers SR6LT and SR8RT for the p53 exon 8 region.
The PCR products were furthermore purified by Chroma spin
column (Clontech Laboratories) and then subjected to sequencing
using a double-strand cycle sequencing system (BRL, Life
Technologies, Inc.) with the primer SR5LT for exon 5 and SR8LT
for exon 8 (Innis et al, 1988).
Immunohistochemistry
Tissue samples were mounted in tissue-Tek OCT compound
(Ames Division, Miles Laboratory, Elkhart, IN, USA), and 8-mm
sections of each skin cancer specimen were cut, air-dried and fixed
in acetone for 10 min. Immunological detection was performed
using anti-p53 monoclonal antibody pAbDO-1 (Oncogene
Science, Inc., Manhasset, NY, USA), which recognizes both wild-
type and mutant forms of the p53 protein. The binding of the
antibody was visualized by the avidin–biotin complex
peroxidase technique, using a sensitive Vectastain Elite kit (Vector
Laboratories, Burlingame, CA, USA) immunoperoxidase system.
RESULTS
Thirty-nine tumour samples and normal tissue samples were
collected from 23 patients with Bowen’s disease, seven patients
with BCC and nine patients with SCC. Genomic DNA was
Exon 5-1 (aa 126-185)
1N 1T 3N 3T 5N 5T 6N 6T 7N 7T
A
Exon 5-2 (aa 161-188)
11N 12N 13N 14N 15N 16N 17N
11T 12T 13T 14T 15T 16T
B
Exon 7
18N 19N 20N 21N 22N 23N
23T 18T 19T 20T 21T 22T
Exon 8
Exon 8
C
D
9T 10T 11T 12T 13T 14T 15T 16T
9N 10N 11N 12N 13N 14N 15N 16N
32N 33N 34N 35N 36N 37N 38N
32T 33T 34T 35T 36T 37T
Figure 1 PCR-SSCP analysis of p53 mutations in arsenic-related skin
cancers. Representative samples are shown for exons 5 (A), 7 (B) and
8 (C, D). An electrophoretic mobility shift of the bands differs between the
tumour (T) and its paired normal tissues (N), representing a different
conformer of the fragment and suggesting the presence of mutations in
these exons. The representative normal PCR-SSCP results of exon 7 are
shown in (C). Note, no electrophoretic mobility shift over the samples tested
suggests normal conformations over these samplesp53 mutation in arsenic-related skin cancers 1083
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extracted from the tumour and normal tissues and then PCR-SSCP
was performed to screen the alterations of p53 gene from exon 2 to
exon 11. The results are summarized in Table 1. After neutral
polyacrylamide gel electrophoresis, the analysis of exon 7 showed
mobility shift bands in cases 3 and 20 (Figure 1B); the analysis of
exon 5 showed mobility shift bands in cases 6, 11, 16, 22, 24 and
31, in addition to the normal bands (Figure 1A). Moreover, the
SSCP patterns revealed that the mobility shift patterns of cases 11,
16 and 22 were the same. In analysis of exon 8, the mobility shift
was also observed in cases 4, 10, 15, 30, 34, 36, 37 and 39 (Figure
1-C, D). No significant DNA mobility shift was observed in the
analysis of other exons (data not shown).
PCR products displaying a mobility shift on SSCP analysis were
directly sequenced. The results of direct sequencing were compared
Case 6
ATCG
N
ATCG
T
A
Codon 149
C
T
T/C
Case 11
ATCG
N
ATCG
T
B
Codon 175
C
C
A/G
Case 10
ATCG
N
AT C G
T
C
Codon 273
T
C
C/G
Case 15
ATCG
N
ATCG
T
D
Codon 298
G
A
A/G
Figure 2 Nucleotide sequencing analysis of the mutations in arsenic-related skin cancers. Each mutation in the tumour cells (T) shown is matched to a normal
adjacent skin tissue (N). The codon at which the mutation occurs is indicated. Each sequence is shown 5¢ (bottom) to 3¢ (top). Arrows point to bands
corresponding to mutated basepairs. (A) Sequencing gel shows a p53 point mutation at codon 149 in tumour cells of case 6 resulting in a change in the
encoding amino acid from serine to phenylalanine. (B) A p53 point mutation at codon 175 in tumour cells of case 11 results in a change in the encoding amino
acid from arginine to histidine. (C) Sequencing gel reveals a point mutation at codon 273 in the tumour cells of case 10, results in a change in the encoding
amino acid from arginine to proline. (D) A point mutation at codon 298 in the tumour cells of case 15 resulting in a silent mutation1084 C-H Hsu et al
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Figure 3 Immunohistochemical studies of p53 protein in arsenic-related skin cancers. Cryostat sections were fixed in acetone and stained with anti-p53
monoclonal antibody pAbDO-1 and detected by the peroxidase–antiperoxidase method. The studies were counterstained with haematoxylin. Positive staining
was found over the skin cancer cells of a representative case with Bowen’s disease (A, ´ 500; B, ´ 250). Note the intense nuclear brownish staining in the
majority of tumour cells limited to the superficial areas. The brownish staining was the result of enzyme reaction with substrate diaminobenzidine, and absence
of staining over the control section occurred when the primary antibody was replaced with non-immune antiserum (C, ´ 500; D, ´ 250). Overexpression of p53
protein was also noticed in the pathological sections of SCC patients (E, ´ 500). Note the brownish intranuclear staining found in the cancer cells passed the
basal membrane and infiltrated in the dermis (F, ´ 250). The immunohistochemical results of a normal skin tissue stain with pAbDO-1 monoclonal antibody. No
obvious nuclear staining was observed over the whole area, indicating that normal p53 level in the normal skin tissue is rather lowp53 mutation in arsenic-related skin cancers 1085
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to those of the controls. The results indicated that the mutation sites
in exon 5 were found to be at codon 149 (TCC®TTC) in one case
(Figure 2A), resulting in a change from serine to phenylalanine in
the protein; at codon 175 (CGC®CAC) in three cases, resulting in a
change from arginine to histidine (Figure 2B); at codon 174
(AGG®CGG) in one case, resulting in a silent mutation; and at
codon 172 (GTT®GCT) in one case, resulting in a change from
valine to alanine in the protein. The mutation sites in exon 7 were
found to be located at codon 249 (AGG®AAG) in one case, leading
to a substitution of lysine for arginine in the protein, and at codon
253 (ACC®ACG) in one case, leading to a silent mutation. In
addition, the mutation sites in exon 8 were found to be at codon 292
(AAA®AAT) in one case, leading to a substitution of asparagine
for lysine in the protein; at codon 273 (CGT®CCT) in three cases
(Figure 2C), leading to a substitution of proline for arginine in the
protein; at codon 284 (ACA®AAA) in one case, resulting in a
change from threonine to lysine and at codon 298 (GAG®GAA) in
one case; and at codon 289 (CTC®CCT) in one case, leading to a
silent mutation (Figure 2D).
In immunohistochemical staining analysis, ten of 23 cases with
Bowen’s disease showed that their tumour cells were limited to the
epidermis. The tumour cells displayed predominantly brown
nuclear staining, indicating the overexpression of the p53 protein
(Figure 3A, B). On the other hand, the pathological sections of
SCC patients revealed that the cancer cells passed the basal
membrane and infiltrated to the dermis, also indicating the over-
expression of the p53 protein (Figure 3E).
DISCUSSION
The tumour samples we collected for this study were from resi-
dents in the blackfoot disease endemic area of Taiwan where the
arsenic content in the well water is reportedly high. Several statis-
tical analyses showed that the residents who live in the blackfoot
disease endemic area have a higher arsenic species content in urine
and a higher occurrence of skin, bladder and lung cancers than
those who live in other areas of Taiwan (Tseng et al, 1968; Chiang
et al, 1993; Hsueh et al, 1998). Arsenic is known to influence cell
division (Debec et al, 1990), and increases chromosomal breaks,
sister chromatid exchange and morphological transformation in
mammalian cells (Magos et al, 1991). Numerous studies on
cultured cell and animal models have shown that arsenic may
generate reactive oxygen species to exert its toxicity (Lee-Chen et
al, 1993; Cavigelli et al, 1996; Lynn et al, 1998), enhance gene
amplification and inhibit DNA repair process (Lee et al, 1988).
Shibata et al suggested that inorganic arsenic compounds act as co-
carcinogens rather than primary carcinogens in vivo as well as in
vitro (Shibata et al, 1994). The arsenic-induced cellular changes
may help increase our understanding of human carcinogenesis.
The results of sequencing showed six types of p53 mutations.
One of the types was G:C®A:T transition. The mutation rate was
38%. These results agreed with previous published results of the
analysis of p53 alterations in bladder cancer from the blackfoot
disease endemic area in Taiwan (Shibata et al, 1994), but were
much lower than seen in UV-induced skin cancers (Sato et al,
1993; Inga, 1998). However, we could not neglect the possibility
that UV may be involved in the cancer development. The mutation
hot spot (codon 175) found in three cases in our study was the
same hot spot found in Shibata et al, (1994) study. Additionally,
the hot spot has been found to be rare in bladder cancers from
other areas and in UV-induced skin cancers (Ziegler et al, 1993;
Shibata et al, 1994). The other mutation types (A:T®T:A,
G:C®C:G, G:C®T:A, and A:T®C:G) are related to chemical
damage of DNA (Matsumura et al, 1996). Furthermore, we
compared our results with the results of UV-induced skin cancer
done by Nakazawa et al (1994) and Ziegler et al (1993). The
occurrence of two types of mutations (C®T or CC®TT) which
were predominantly found in UV-induced DNA damage were
compared using c2 analysis and Fisher’s exact test. Significant
difference was found between UV-induced skin cancers and
arsenic-related skin cancers (P < 0.05). These results suggest that
UV mutations have little impact on carcinogenesis. Therefore,
arsenic exposure may be a major cause of the cancer.
In analysis of p53 protein overexpression, we observed positive
staining in 43.5% (10/23) of the cases with Bowen’s disease and
55.6% (4/9) of the SCC patients. The prevalence of p53 protein
overexpression in UV-induced skin cancer ranged from 20% to
80% in previous reports (Nagano et al, 1993; van Kranen et al,
1995, 1997; Berg et al, 1996; Nataraj et al, 1996). The significant
positive rate in Bowen’s disease patients suggested that p53 gene
mutation commonly occurred in the early stages of arsenic-related
skin cancer. PCR-SSCP analysis did not detect p53 gene alter-
ations in four of 15 immunohistochemically stained positive cases.
This result may be due to the detection limitation of PCR-SSCP, or
the mutation occurring on an intron where it was not detected. p53
protein overexpression was not found in five of 15 cases with p53
gene mutations; this may be due to the mutation belonging to
silent mutation or missense mutation, which does not affect the
half-life of p53 protein (Lin et al, 1994). The results of this study
indicated that the p53 gene mutation rates, sites and types in
arsenic-related skin cancer were significantly different from those
in UV-induced skin cancer. This proved that, at the molecular
level, the cancers occurred at the same portions, but were induced
by different carcinogens, and that the p53 gene mutation was asso-
ciated with the carcinogenesis of arsenic-related skin cancers.
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